Currently serving as Corporate Officer and Chief Financial Officer of Provectus Biopharmaceuticals, Inc., Peter Culpepper has an extensive background in capital fund raising, corporate profit and loss reporting, investor management, and business planning. Peter Culpepper has proved his strengths as a strategic leader throughout his career, guiding companies through optimized internal controls to create a strong underpinning of financial compliance and integrity.
At Provectus Biopharmaceuticals, Peter Culpepper heads the SEC filing division and manages investor financing for the company in order to facilitate the firm's work as a biopharmaceutical company specializing in dermatology and oncology therapies. Mr. Culpepper works in concert with lawyers and auditors to ensure that Provectus complies entirely with SOX 404. He also oversees the company's management structure and presents his recommendations about management to the Board of Directors.
Prior to joining Provectus Biopharmaceuticals in 2004, Peter Culpepper served for three years as a Management Consultant at Felix Culpepper International, Inc. He worked with corporations in all stages of development on a wide range of questions including valuation, business planning, and fundraising. Peter Culpepper is formerly a registered representative with AXA Advisors, LLC.
From 2000 to 2001, Peter Culpepper was Corporate Controller and Chief Accounting Officer of Neptec, Inc., a fiber-optic component manufacturer. In this role, he also served as Corporate Secretary of Management on the board of the company, participating in a wide range of auditing activities and pre-IPO preparations.
Peter Culpepper held a number of positions at Metromedia Affiliated Companies between 1998 and 2000, including serving as Group Finance Director of Metromedia International Group in Austria, Assistant Corporate Controller of Metromedia International Group in the United States, and Network Controller of Metromedia Fiber Network. From 1993 to 1998, Peter Culpepper worked as Accounting Manager, Assistant Regional Controller, National Accounts Division Controller, and finally Director of Accounting at Paging Network, Inc.
Peter Culpepper holds a BA in Philosophy from The College of William & Mary, an Associate of Applied Science (AAS) in Accounting from Northern Virginia Community College (NOVA), and an MBA in Finance from the University of Maryland's Robert H. Smith School of Business.
Provectus Starts Clinical PV-10 Trials for Melanoma Treatment
Peter Culpepper serves as the chief financial officer and chief operating officer of Provectus Biopharmaceuticals, a company that engineers treatments for cancer. At the beginning of 2016, Peter Culpepper’s company confirmed that the first round of human patients had received PV-10 in the phase 3 international trial of the drug. This trial will determine the efficacy of the treatment in cases of advanced cutaneous melanoma.
In addition, Provectus undertook a phase 1b/2 clinical trial to look at the combination of PV-10 with an anti-PD-1 therapy manufactured by Merck called Keytruda among patient populations with stage 4 melanoma.
In both trials, effectiveness will be gauged by progression-free survival (PFS) comparisons using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. PFS measurements will be taken every 12 weeks for up to 18 months. Researchers will also look at complete response rate and overall survival data.
The phase 3 trial currently has seven enrollment sites across the United States and one in Australia, and Provectus plans to continue recruiting.
Provectus Biopharmaceuticals - Data on Immunologic Effects of PV-10
Based in Knoxville, Tennessee, Peter Culpepper serves as the chief operating officer and chief financial officer of Provectus Biopharmaceuticals, Inc. At the beginning of 2016, Peter Culpepper also became the interim chief executive officer for Provectus, a clinical-stage biopharmaceutical company that develops dermatology therapies and oncology treatments for various cancers.
In February of 2016, Provectus highlighted data on the immunologic outcomes of its investigational cancer therapy, PV-10, on colon cancer cells at the 11th Annual Academic Surgical Congress. The abstract was presented by a member of the research team, N. M. Kunda, who works in oncology at the University of Illinois at Chicago.
During the presentation in Jacksonville, Florida, Dr. Kunda reported that PV-10 showed signs of being toxic to cells during in vitro tests on colon cancer. Dr. Kunda also noted that testing showed evidence of cell arrest, autophagy, apoptosis, and endoplasmic reticulum stress. Provectus’ chief technology officer, Eric Wachter, stated that the data presented at the conference further explains the mechanisms behind PV-10’s effect on solid tumors as an ablative immunotherapy.
Peter Culpepper holds an MBA in finance from the University of Maryland and is the CFO of Provectus Biopharmaceuticals. Peter Culpepper plays a significant role in helping the company advance therapies that target the deadliest of cancers, including liver cancer.
Liver cancer is a type of cancer that begins in the cells of the liver. While the liver plays host to many types of cells, the most common are hepatocytes, hence hepatocellular cancer is the most common form of liver cancer.
Liver cancer spreads silently, and most of its symptoms don’t show up until later when the cancer has progressed. Symptoms include pain on the upper-right side of the abdomen, loss of appetite, weight loss, nausea and vomiting, abdominal swelling, and in some cases, yellow skin discoloration.
In a majority of people, liver cancer develops in the later stages of chronic liver diseases such as cirrhosis and hepatitis B and C, and in these cases, the causes of liver cancer can be traced back to dietary, environmental, and lifestyle factors.
Peter Culpepper: Financial Executives Networking Group Enriches Members’ Knowledge
A senior finance executive, Peter Culpepper is currently chief operating officer and chief financial officer at Provectus Biopharmaceuticals, based in Knoxville, Tennessee. Pete Culpepper is a member of the Financial Executives Networking Group.
The Financial Executives Networking Group (The FENG) has grown from a small Connecticut-based organization to an international organization with more than 44,000 members. Currently, FENG members represent more than 8,000 private and 2,500 public companies. Around 40 percent of FENG members work at companies with annual sales in excess of $500 million, with 55 percent of FENG members working at companies that employ more than 500 individuals.
The FENG strives to provide opportunities for senior financial executives to network and share job leads. Today, The FENG publishes an email newsletter five times a week and 52 weeks a year. Each month, The FENG publishes more than 1,500 pages of financial job opportunities and career advice to support members’ career growth. In addition, The FENG collaborates with other networking groups to host conference calls and events to keep members updated on key financial trends.
With geographic chapters and functional special interest groups, The FENG has a range of opportunities to meet the needs of all members. Thanks to a combination of innovative programs and outreach, the FENG’s membership is growing at 15 percent annually.
Financial executive and corporate strategy expert Peter Culpepper holds Certified Public Accountant (CPA) status in the states of Maryland and Tennessee. Here, he presents the steps necessary to achieve this certification.
Naturally, Certified Public Accountants must have completed extensive accounting coursework. The American Institute of CPAs (AICPA) recommends a minimum of 150 college-level semester hours. Once this coursework is completed, a candidate must then sit the Uniform CPA Examination. The examination is the only element in CPA certification that does not vary by state; every potential CPA in the nation sits the same exam. The exam consists of four sections that result in a total of 14 testing hours.
Following completion of the exam, a candidate must demonstrate sufficient accounting experience before receiving a CPA license. Some states do grant a preliminary certificate after passing the exam, but a person may not practice as a CPA until receiving full licensure. The length of experience required for this status varies by state, but typically involves at least two years in public accounting. Many states also accept nonpublic (such as government) accounting experience, although candidates taking this route must often show more years of experience than their publicly practicing counterparts.
Peter Culpepper: The Robert H. Smith School of Business at the University of Maryland is Home to Renowned Center for Financial Policy
Peter Culpepper, a seasoned finance executive and strategic leader, is chief financial officer and chief operating officer of Provectus Biopharmaceuticals. Pete Culpepper earned an MBA with a concentration in finance from the Robert H. Smith School of Business at the University of Maryland.
The Robert H. Smith School of Business at the University of Maryland (Smith School) is home to the renowned Center for Financial Policy. One of the center’s key strategic objectives is facilitating the collaborative exchange of ideas between business, government, and academia. Moreover, the center aims to educate the next generation of leaders on financial policy practices.
As a leader in the financial arena, the center examines issues of importance to both public and private sectors. In addition, the center provides a forum for knowledge transfer between research leaders in financial policy, policy makers, and policy institutions. The center has key relationships with U.S. and non-U.S. federal government officials, financial institutions, corporations, affiliated trade associations, and others.
By building on these high-value relationships and leveraging the expertise of the distinguished Smith School faculty, the Center has research tracks focused on corporate governance, financial institutions/consumer finance, risk management, management and market design, and emerging markets.
CFO stands for Chief Financial Officer, a senior management executive who is in charge of overseeing all financial activities for a company. CFOs’ job responsibilities can be separated into three spheres. They act as controllers, providing accurate financial information about the company to stakeholders. CFOs handle treasury duties and determine a company's investment options. This involves managing the company's capital structure and balancing its debt and equity. Additionally, CFOs are responsible for developing economic strategy and forecasting.
In charge of the entirety of a company's finances, CFOs are exposed to a considerable amount of liability in the event of something going wrong, such as fraud or embezzlement. For this reason, the position generally requires a high level of training.
About Peter Culpepper:
For the past nine years, Peter Culpepper has functioned as the Chief Financial Officer and Chief Operating Officer of Provectus Biopharmaceuticals, located in Knoxville, Tennessee.
The Benefits of Attaining an MBA By Peter Culpepper
There are a variety of good reasons why those who are interested in furthering their career in business should consider acquiring a Master of Business Administration. It develops the leadership skills needed to deal with real-world situations and adds to the understanding of business practices in general. This leads to a competitive edge that will allow the holder of an MBA to climb more rapidly through a company's ranks. When an economic slowdown affects a particular field, an MBA may make its holder less likely to be laid off, or allow for a switch in career path. The expertise gained through MBA courses also makes it easier to launch a business. Additionally, networking performed during the academic process can lead to the development of vital contacts. All of these advantages can ensure a successful and more lucrative career.
About Peter Culpepper:
Pete Culpepper holds an MBA from the University of Maryland. He currently serves as the CFO for a prominent pharmaceutical company.
Taking Steps to Prevent Melanoma. By Peter Culpepper
An ounce of prevention is worth a pound of cure, reads the old adage, and this is especially true of overexposure to the sun, which can lead to melanoma, one of the deadliest forms of cancer. While certain risk factors such as genetics, skin type, and family history cannot be changed, it is still true that all individuals can reduce their risk by taking certain precautions. Ultra violet (UV) rays, while less intense than UVB rays, can still cause sun damage and should be avoided as much as possible. Eschewing tanning beds and avoiding the sun during the most intense times of the day, usually from 9 a.m. to 3 p.m., are good first steps to take. Individuals can also don long-sleeved shirts and wide-brimmed hats, seek shade whenever possible, and wear a broad-spectrum sunscreen with a sun protection factor (SPF) of at least 15. It is also a good idea to monitor moles and dark lesions and have them examined or removed by a qualified dermatologist.
About the author: Financial professional Peter Culpepper is currently CFO of Provectus Biopharmaceuticals, Inc., a company focused on developing new therapies for the treatment of breast cancer, metastatic melanoma, psoriasis, and other diseases.
Peter Culpepper: The FDA Gives Benefits to Companies Seeking Treatments for Rare Diseases
Peter Culpepper is the current Chief Financial Officer and Chief Operating Officer of Provectus Biopharmaceuticals, Inc., a company researching potential treatments for rare diseases. A CPA with over 25 years of experience, Culpepper earned his MBA from the University of Maryland.
The majority of medical treatments are researched and developed by private companies seeking to make money off of pharmaceutical sales. Unfortunately, when a small number of people suffer from a disease, such as ALS, companies have little financial incentive to investigate potential treatments. In an effort to increase the treatments available to those suffering from rare diseases, the U.S. Congress passed the Orphan Drug Act in 1983.
Through the Act, the U.S. Food and Drug Administration provides incentives to those companies researching treatments for diseases specifically impacting fewer than 200,000 Americans or fewer than 5 people per 100,000. Benefits include tax reductions and exclusive rights to the developed medications. Due to the lack of potential study participants, the FDA also lowers the number of people required for clinical trials. Other countries and the European Union have similar orphan disease treatment incentives.
"Treatment Options for Childhood Cancer Continue to Advance," by Peter Culpepper
About the Author: As Chief Financial Officer and Chief Operational Officer of Tennessee-based Provectus Biopharmaceuticals, Peter Culpepper helps the company work to eliminate the potentially devastating side effects of cancer treatment for patients and their families. A graduate of the University of Maryland, where he earned his Master of Business Administration, Peter Culpepper began his current role after a long career in accounting and finance.
Childhood cancer, the leading cause of death in children under the age of 15, affects approximately 11,000 children each year. The diagnosis often proves frightening for both the patient and his or her loved ones. Moreover, treatment options often carry significant side effects, such as nausea, weakness, and discomfort. Nonetheless, medical science continues to make incredible advances in the treatment of cancers; the five-year survival rate for childhood cancer has increased to 80% from less than 50% just 30 years ago.
The most commonly diagnosed forms of childhood cancer include leukemia, kidney cancer, tumors of the brain or nervous system, eye cancer, and bone cancer. While treatment methods like chemotherapy and radiation often provide positive results, they also sometimes propagate immediate and long-term side effects. Pediatric oncologists advise patients and their families to undergo regular follow-up examinations following childhood cancer treatment to minimize any potential risks for future health.
